Pharmacokinetics of atenolol in relation to renal function.
The pharmacokinetics of atenolol were determined following acute intravenous and chronic oral administration to 20 subjects with a glomerular filtration rate (GFR) between 5 and 113 ml/min. Plasma levels in a further 5 patients on haemodialysis were measured after intravenous treatment. The mean half life of elimination increased from 5.9 h in patients with normal renal function to 42.1 h in preuraemic patients (GFR less than 10 ml/min) following a single i.v. dose. The half life of elimination following chronic oral administration was not significantly different. Mean peak plasma concentrations increased from 540 ng/ml in patients with normal renal function to 1493 ng/ml in preuraemic patients following chronic oral treatment with 100 mg/day. The mean half life of elimination during a single haemodialysis treatment was 4.3 h. In patients with a GFR greater than 10 ml/min the normal daily dose of atenolol should be employed, in patients with a GFR between 10 and 30 ml/min the dose should be reduced by half, and in patients with a GFR less than 30 ml/min a reduction by three quarters of the normal dose is recommended.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001262:Atenolol / Q000097:blood / Q000378:metabolism*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007275:Injections, Intravenous; D007674:Kidney Diseases / Q000503:physiopathology*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000378:metabolism*; D006435:Renal Dialysis
D011412:Propanolamines; D001262:Atenolol